Texas Woman Files Lawsuit Against Xarelto Alleging Drug Caused Signs Of Internal Bleeding
A Texas woman has filed a lawsuit in the federal court of the Eastern District of New York against the makers of Xarelto, a new class of blood thinner. In it, she alleges that she sustained serious injuries, signs of internal bleeding due to the company’s failure to warn her about the potential risks of using the drug and that the company failed to conduct safety testing that was sufficient before placing the blood thinner on the market. Her lawsuit is similar to many others filed against Janssen and Bayer AG. The case is listed under the federal court docket number 1:14-CV-04524 and is available in its entirety to read below.
December 7, 2015 – BloodThinnerHelp.com reports that a Texas woman has filed a lawsuit in the Eastern District of New York alleging that Janssen Pharmaceuticals and Bayer AG, the manufacturers of Xarelto, failed to provide sufficient warnings to consumers about the potential risk of the signs of internal bleeding with this blood thinner. In federal court, the latest complaint was filed under 1:14-CV-04524.
The lawsuit contains details about how the drug was prescribed to treat a condition known as atrial fibrillation. This condition can cause strokes due to blood clots. As a preventative measure, cases of this type are commonly treated with blood thinners. However, just five months after taking the blood thinner, she experienced an internal bleed that was life threatening. While the complaint does not specify much of the details of the injury, it does state that specialized care will be required due to long tern health effects that occurred as a consequence of the bleed.
After the U.S. Food and Drug Administration approved Xarelto in 2011, it was released to the market for prescription. Initially, the new drug was regarded as an option that was revolutionary, because it did not require a special diet, adjustments by physicians, or regular monitoring. However, once consumers realized that there was no antidote, this early excitement was short lived. Currently, it is seen by many to be the market’s most dangerous blood thinner.
Because there is no antidote, if a patient taking Xarelto begins to show the signs of internal bleeding after an injury, there is no way to get the blood to clot by countering the effects of the drug. In order to keep the patient alive when this happens, blood transfusions and other extreme measures to save their life must be used. In addition, operations are sometimes necessary when pools of blood develop in the spine or brain in order to relieve the built up pressure in the body by draining the blood.
Vitamin K provides an antidote for traditional blood thinners. Because of this, the effects of the traditional blood thinner are counteracted and blood clots can form when an injury occurs. It is the difference between living and dying in these cases.
Federally, there have been about 2,000 cases filed against Xarelto for bleeding that cannot be controlled. In the Eastern District of Louisiana, the Honorable Judge Eldon Fallon is overseeing the consolidation of these cases in Multidistrict litigation number 2To 592. Attorney Joseph Osborne is working to make sure that everyone has the opportunity to evaluate their legal rights if they were affected by Xarelto as these cases are prepared for trial. There may be a significant compensation for individuals who suffered adverse health effects and any signs of internal bleeding due to using Xarelto. To those involved, free legal consultations are available from attorney Osborne.
Please contact our attorney today for additional information or to ask questions about the Xarelto bleeding lawsuits.